Aryabhatta Sadhu: Which Part of Haemostasis Has Failed First?
Aryabhatta Sadhu, Attending Consultant and Head of Transfusion Medicine at Fortis Hospital Shalimar Bagh, New Delhi, shared a post on LinkedIn:
“A bleeding patient with ‘acceptable’ platelets can still be haemostatically unsafe.
One common error in active bleeding is looking at haemoglobin and platelet count first, while fibrinogen is checked late – or corrected even later.
That is backwards physiology.
In major bleeding, fibrinogen is often one of the earliest haemostatic factors to fall.0
A patient may have a platelet count of 70,000–90,000/µL and still continue bleeding because the clot being formed has poor fibrin strength.
The clinical decision point is simple:
Before reflexively asking for ‘2 FFP and 1 platelet,’ ask:
What is the fibrinogen?
If the patient is actively bleeding and fibrinogen is low, correction with cryoprecipitate or fibrinogen concentrate should be considered early, depending on local availability and protocol.
This is even more critical in obstetric haemorrhage, trauma, liver disease, cardiac surgery, DIC-like states, and massive transfusion scenarios.
Platelets are not cement by themselves.
FFP is not a universal correction fluid.
Cryoprecipitate is not a ‘last step’ component.
A bleeding patient needs haemostatic reconstruction: red cells for oxygen carriage, plasma factors when coagulation is globally impaired, platelets when primary haemostasis is inadequate, fibrinogen when clot strength is failing, calcium when citrate load rises, and temperature/pH correction because enzymes do not work in a hostile physiology.
Practical takeaway:
In active bleeding, do not treat the CBC alone.
Ask for:
- PT/INR
- aPTT
- fibrinogen
- platelet count
- ionised calcium
- ABG/lactate
- TEG/ROTEM if available
The question is not ‘Which blood component is pending?’
The question is:
Which part of haemostasis has failed first?
That is where Transfusion Medicine must move beyond blood issue and function as bedside haemotherapy consultation.”

Other posts featuring Aryabhatta Sadhu with Hemsotasis Today.
-
Jun 22, 2026, 16:45Shivangi Harankhedkar: From Disease Management to Cure – The Promise of CRISPR in Hemoglobinopathies
-
Jun 22, 2026, 16:39Vikram Sinai Talaulikar: Haematology and Female Hormone Health Intersect at Multiple Levels
-
Jun 22, 2026, 16:35Sehrish Chaudhary: Advancing Transfusion Medicine Through Global Collaboration at ISBT 2026
-
Jun 22, 2026, 15:54Ready to Build Your ISTH 2026 Schedule?
-
Jun 22, 2026, 15:36Wolfgang Miesbach: What the Latest Gene Therapy Setbacks Mean for Haemophilia Care
-
Jun 22, 2026, 15:26Suvro Sankha Datta: Advancing Transfusion Medicine Through the Establishment of a Red Cell Genotyping Facility
-
Jun 22, 2026, 15:08Apixaban vs. Rivaroxaban in Acute VTE – Uncoiling COBRRA and Its Clinical Implications – Anticoagulation Forum
-
Jun 22, 2026, 14:41Ilkin Aygun Soyalp: Novel Substrate Recognition Broadens the Biological Role of DPF-3
-
Jun 22, 2026, 14:29Swarnava Roy: Linking Angiotensin Signaling to Oxidative Stress and Organ Damage in Sickle Cell Anemia